- In May 2024, Pfizer Inc. announced the expansion of its lyophilization facilities at its Kalamazoo, Michigan plant to support increasing demand for stable injectable biologics and mRNA-based therapies. The investment is aimed at enhancing production scalability and minimizing cold chain dependency, reinforcing Pfizer’s leadership in innovative drug delivery technologies
- In April 2024, Recipharm AB, a leading contract development and manufacturing organization (CDMO), launched a new state-of-the-art lyophilization line at its facility in Brescia, Italy. This expansion is designed to meet rising global demand for freeze-dried injectables, particularly in the oncology and rare disease sectors, and strengthens Recipharm’s presence in the European contract manufacturing market
- In February 2024, Baxter International Inc. collaborated with the U.S. Biomedical Advanced Research and Development Authority (BARDA) to enhance domestic manufacturing of lyophilized injectables used in emergency preparedness. The partnership focuses on improving supply chain resilience and increasing national stockpiles of temperature-stable essential medicines
- In January 2024, Aurobindo Pharma Limited received U.S. FDA approval for its lyophilized generic version of Meropenem for Injection, expanding its portfolio of hospital-focused sterile injectable products. This milestone enhances the company’s position in the competitive injectable generics market, offering cost-effective solutions for critical care treatments
- In December 2023, Cipla Limited announced the commercialization of its in-house developed lyophilized oncology drug, Docetaxel Injection USP, in the Indian market. The product launch aims to offer affordable, high-quality chemotherapy treatments with improved shelf life and storage benefits, reinforcing Cipla's commitment to accessible cancer care
- In November 2023, Vetter Pharma-Fertigung GmbH & Co. KG, a global CDMO, began construction on a new facility in Austria dedicated to large-scale lyophilized injectable drug production. The facility will support biotech and pharmaceutical partners with advanced fill-finish capabilities for high-value biologics and sensitive compounds
- In October 2023, Hikma Pharmaceuticals PLC expanded its lyophilized injectable offerings in the U.S. with the launch of additional generic anti-infectives and cardiovascular treatments. This move supports hospitals in managing drug shortages by providing reliable supply alternatives with extended shelf life
